Search results
Showing 991 to 1005 of 2107 results for technology appraisal
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Cochlear implants for children and adults with severe to profound deafness (TA566)
Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
advice Our scientific advice service has helped companies reduce their NICE appraisal timeline by around 3 months . We'll review key...
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.
View recommendations for TA157Show all sections
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over (TA1157)
Evidence-based recommendations on givinostat (Duvyzat) for treating Duchenne muscular dystrophy in people 6 years and over.
Thopaz+ portable digital system for managing chest drains (HTG465)
Evidence-based recommendations on Thopaz+ for managing chest drains.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.